Companies Announce Future Plans, Partnerships, and Financing Deals at J.P. Morgan Conference in San Francisco
January 17, 2015
By Andrew Hoglund

The J.P. Morgan 33rd Annual Healthcare Conference held in San Francisco this past week is a huge conference for medical device companies. It’s a conference that nearly all the major healthcare companies attend and is a great place for companies to show off new products, talk about what they are planning for the future, and announce new partnerships. This is one of the biggest medical device conferences of the year. Oracle, not normally known for being involved in medical device, announced that it will use Proteus’ digital pill in its

Read More

Six Companies Received Millions In Funding This Week
January 10, 2015
By Andrew Hoglund

Several companies raised millions of dollars to help either further develop or market their products this week. Cerus, CardioFocus, 23andMe, PureTech, GlySens, and Sera Prognostics all received funding, either through Series funding, through deals with other companies, or through fund raising of their own. Cerus is in the process of raising $70 million through a public offering of 12.7 million shares at $5.50 a share. Cerus’s stock has jumped in the last couple weeks because of several FDA approvals for their Intercept Blood System to treat blood products. The system

Read More

Bay Area Medical Device Companies Doing Well
December 20, 2014
By Andrew Hoglund

There were several medical device companies from the Bay Area that made the news this week. A small company in South San Francisco, diaDexus, received FDA 510(k) clearance for its PLAC Activity test to assess coronary heart disease risk. The new test checks the activity of Lp-PLA2 (Lipoprotein-Associated Phospholipase A2) in human plasma and serum. The enzyme assay is based on a National Institutes of Health-funded study of 4,500 people with no prior history of heart problems which found that elevated Lp-PLA2 activity levels are associated with a much greater

Read More